Vice President, US Medical Affairs and Respiratory Therapeutic Area Head
Dr. Karin Rosén is Senior Vice President, US Medical Affairs and responsible for Medical Governance and Medical Affairs activities in the US, oversee regional Phase IIIb/IV clinical planning in the market and serve as the senior physician for the US and the medical partner to the President of the US Pharmaceuticals business.
Prior to joining GSK, Karin was Senior Vice President of US & Global Medical Affairs at Aimmune Therapeutics where she led the US and Global Medical Affairs organization, which included building and managing headquarters and field-based teams in the US and around the world and designing novel drug development programs to treat food allergies. Earlier in her career, Karin held leadership roles in medical affairs and medicine development at Genentech where she led international clinical research and product development programs in respiratory and immunology. She has also served as a scientific advisor to multiple companies on development strategy across therapeutic areas and has extensive research and academic experience.
A native of Sweden, Karin holds M.D. and Ph.D. degrees from Lund University in Lund, Sweden. She will split her time between the RTP and Philadelphia locations and San Francisco where she resides with her family.
Find out more about our CEO and Board of Directors
Board of Directors
The Board of Directors is responsible for the group's system of corporate governance and is ultimately accountable for the group's activities, strategy, risk management and financial performance.
Find out more
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
GSK in the US
GSK is dedicated to helping grow the US economy and supporting communities by creating high-quality jobs in areas like R&D, manufacturing, and sales.
Our Pharmaceuticals business is made up of innovative and established medicines and holds leading market positions in respiratory disease and HIV.
Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. We deliver over two million vaccine doses per day to people living in over 160 countries.